Pulmonary Circulation (Oct 2021)

Liver abnormalities in pulmonary arterial hypertension

  • Nils P. Nickel,
  • Gian M. Galura,
  • Marc J. Zuckerman,
  • M. Nawar Hakim,
  • Haider Alkhateeb,
  • Debabrata Mukherjee,
  • Eric D. Austin,
  • Gustavo A. Heresi

DOI
https://doi.org/10.1177/20458940211054304
Journal volume & issue
Vol. 11, no. 4
pp. 1 – 12

Abstract

Read online

Pulmonary arterial hypertension (PAH) is a cardiopulmonary disease with high mortality. In recent years, it has been recognized that PAH is a multi‐organ system disease, involving the systemic circulation, kidneys, skeletal muscles, and the central nervous system, among others. Right heart failure produces congestive hepatopathy, a disease state that has direct consequences on liver biochemistry, histology, and systemic glucose and lipid metabolism. This article aims to summarize the consequences of congestive hepatopathy with an emphasis on liver biochemistry, histology, and PAH‐targeted therapy. Furthermore, PAH‐specific changes in glucose and lipid metabolism will be discussed.

Keywords